Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis
Authors:
- 1 December 2016
- journal article
- case report
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 11 (12) , 2238-2240
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewEuropean Journal of Cancer, 2016
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Opportunistic infections in patients treated with immunotherapy for cancerJournal for ImmunoTherapy of Cancer, 2014
- Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsisJournal of Leukocyte Biology, 2010
- Programmed Death (PD)-1:PD-Ligand 1/PD-Ligand 2 Pathway Inhibits T Cell Effector Functions during Human TuberculosisThe Journal of Immunology, 2008
- The PD-1/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungusHistoplasma capsulatumProceedings of the National Academy of Sciences, 2008
- PD-1:PD-L1 Interactions Contribute to the Functional Suppression of Virus-Specific CD8+ T Lymphocytes in the LiverThe Journal of Immunology, 2007
- Expression of B7-H1 on Gastric Epithelial Cells: Its Potential Role in Regulating T Cells during Helicobacter pylori InfectionThe Journal of Immunology, 2006
- Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretroviralsThe Lancet Infectious Diseases, 2005